A Melbourne-based immunotherapy company.

Ascend Biopharmaceuticals provides upgrade on clinical trial plan for lead immunotherapy products Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has released an upgrade on the clinical trial pipeline for its lead immunotherapy items treating basal cell carcinoma and breast cancers. The ongoing company programs to begin with a Phase 2 medical trial on ASN-002, an injectable immunotherapy for basal cell carcinoma , by H1 2015. Interim outcomes from the trial are expected in mid-past due 2015 tadalafil-nz.net more info . Ascend in addition has announced programs to begin with a Phase 1b study on a therapeutic tumor vaccine for breast malignancy, ASN-004, in the second half of 2015.